Pharvaris N.V.
PHVS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001830487
In the last 90 days, Pharvaris N.V. insiders filed 0 open-market purchases and 20 sales; 125 institutions reported holding it in 13F filings for Q2 2026, worth $2.23B in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q4 2021
Institutional positions in Pharvaris N.V. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 22
- −3 vs. Q3 2021
- Shares held
- 21.6M
- +15.4K (+0.1%) vs. Q3 2021
- Total value
- $321.1M
- −$59.2M (−15.6%) vs. Q3 2021
- New holders
- 1
- 6 more added
- Sold out
- 4
- 6 more reduced
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PHVS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 125 | $2.23B |
| Q1 2026 | 110 | $1.67B |
| Q4 2025 | 106 | $1.64B |
| Q3 2025 | 83 | $1.44B |
| Q2 2025 | 60 | $792.7M |
| Q1 2025 | 52 | $705.5M |
| Q4 2024 | 54 | $855.8M |
| Q3 2024 | 51 | $834.2M |
| Q2 2024 | 36 | $808.6M |
| Q1 2024 | 35 | $980.5M |
| Q4 2023 | 36 | $1.14B |
| Q3 2023 | 21 | $606.6M |
| Q2 2023 | 21 | $441.6M |
| Q1 2023 | 21 | $173.9M |
| Q4 2022 | 25 | $239.6M |
| Q3 2022 | 21 | $173.6M |
| Q2 2022 | 20 | $494.0M |
| Q1 2022 | 22 | $397.1M |
| Q4 2021 | 22 | $321.1M |
| Q3 2021 | 25 | $380.3M |
| Q2 2021 | 28 | $406.3M |
| Q1 2021 | 33 | $616.5M |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding Pharvaris N.V.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 3,295,109 | $52.1M | 0.00% | −17,750−0.5% | Reduced |
| Foresite Capital Management IV, LLC | 3,261,926 | $46.9M | 9.66% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 3,180,601 | $45.8M | 3.63% | 00.0% | Unchanged |
| Viking Global Investors LPSuperinvestorViking Global Investors | 2,455,536 | $38.8M | 0.11% | +64,019+2.7% | Added |
| General Atlantic LLC | 2,420,155 | $34.8M | 0.27% | 00.0% | Unchanged |
| venBio Partners LLC | 2,303,310 | $33.1M | 5.97% | 00.0% | Unchanged |
| Deerfield Management Company, L.P. (Series C) | 1,581,331 | $22.8M | 0.48% | −27,140−1.7% | Reduced |
| Suvretta Capital Management, LLC | 827,540 | $11.9M | 0.23% | +827,540 | New |
| Cormorant Asset Management, LP | 689,731 | $9.93M | 0.59% | 00.0% | Unchanged |
| Pictet Asset Management SA | 540,811 | $8.56M | 0.01% | −16,248−2.9% | Reduced |
| Novo Holdings A/S | 516,321 | $7.43M | 0.35% | +97,378+23.2% | Added |
| Eventide Asset Management, LLC | 244,925 | $3.88M | 0.05% | 00.0% | Unchanged |
| Millennium Management LLC | 119,558 | $1.89M | 0.00% | −38,195−24.2% | Reduced |
| Goldman Sachs Group Inc | 57,516 | $828.0K | 0.00% | +27,342+90.6% | Added |
| DAFNA Capital Management LLC | 36,720 | $528.0K | 0.13% | +1,646+4.7% | Added |
| Foresite Capital Management V, LLC | 34,142 | $491.0K | 0.12% | −330,000−90.6% | Reduced |
| Perceptive Advisors LLC | 27,000 | $389.0K | 0.01% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 18,643 | $294.0K | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 16,964 | $268.0K | 0.00% | +1,060+6.7% | Added |
| Morgan Stanley | 18,256 | $262.0K | 0.00% | +709+4.0% | Added |
| Bank of America Corp | 500 | $7.00K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 423 | $6.00K | 0.00% | −231−35.3% | Reduced |
| VR Adviser, LLC | 0 | $0 | 0.00% | −552,882−100.0% | Sold out |
| Compagnie Lombard Odier SCmA | 0 | $0 | 0.00% | −16,670−100.0% | Sold out |
| Ensign Peak Advisors, Inc | 0 | $0 | 0.00% | −5,000−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −211−100.0% | Sold out |